| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) b...
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pionee...
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneer...
Canaccord Genuity analyst Sumant Kulkarni maintains Annovis Bio (NYSE:ANVS) with a Buy and maintains $17 price target.
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneer...